| 產(chǎn)品名稱 |
CFPAC-1 |
| 商品貨號(hào) |
B164237 |
| Organism |
Homo sapiens, human |
| Tissue |
pancreas; derived from metastatic: liver |
| Cell Type |
Epithelial |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
ductal adenocarcinoma; cystic fibrosis |
| Age |
26 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Applications |
This cell line is a suitable transfection host. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
hyperdiploid; modal number = 73; range = 65 to 75; several translocations were evident; two to three apparently normal copies of number 7 (to which the cystic fibrosis gene has been mapped) were present in every metaphase examined |
| Derivation |
This line was derived from a ductal adenocarcinoma (liver metastasis) from a patient with cystic fibrosis. |
| Clinical Data |
26 years
Caucasian
male |
| Antigen Expression |
CA19-9 antigen, 12000 units/mL, epithelial keratins |
| Genes Expressed |
carcinoembryonic antigen (CEA), 9 ng/mL; pancreatic oncofetal antigen (POA), 28 ng/mL; adenocarcinoma associated antigen (ACAA), 5000 ng/mL; CA 19-9 antigen, 12000 units/mL; epithelial keratins |
| Cellular Products |
carcinoembryonic antigen (CEA), 9 ng/mL; pancreatic oncofetal antigen (POA), 28 ng/mL; adenocarcinoma associated antigen (ACAA), 5000 ng/mL; CA 19-9 antigen, 12000 units/mL; epithelial keratins |
| Tumorigenic |
Yes |
| Effects |
Yes, in nude mice (passage 34) |
| Comments |
The cells exhibit ion transport activities consistent with cystic fibrosis and express the product of the CF gene (cystic fibrosis transmembrane regulator, CFTR).
CFPAC-1 cells show no effect of cAMP agonists, adenyl cyclase stimulators or phosphodiesterase inhibitors on Cl- flux, but do respond to Ca++ ionophores with increase Cl- efflux.
The cells have the most common form of the CF mutation, deletion of three nucleotides resulting in the absence of phenylalanine at position 508.
CFPAC-1 cells have epithelial morphology and polarization with apical microvilli, tight junctions and gap junctions. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: Air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile |
Amelogenin: X,Y CSF1PO: 10 D13S317: 12 D16S539: 9,11 D5S818: 10,11 D7S820: 8,10 THO1: 8 TPOX: 8 vWA: 17 |
| Population Doubling Time |
32 hrs |
| Name of Depositor |
RA Schoumacher |
| Deposited As |
Homo sapiens |
| References |
Schoumacher RA, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA 87: 4012-4016, 1990. PubMed: 1692630
McIntosh JC, et al. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am. J. Med. 85: 592, 1988. PubMed: 3177424
|
